Related content

Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours

By de Jonge M.J.A.   Verweij J.   van der Gaast A.   Valota O.   Mora O.   Planting A.S.T.   Mantel M.A.   Bosch S.V.D.   Lechuga M.J.   Fiorentini F.   Hess D.   Sessa C.  

European Journal of Cancer, Vol. 38, Iss. 18, 2002-12 ,pp. : 2407-2415

Elsevier

Access to resources Recommend Favorite

Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin) in humans using CFU-GM clonogenic assays and prospective validation

By Moneta D.   Geroni C.   Valota O.   Grossi P.   de Jonge M.J.A.   Brughera M.   Colajori E.   Ghielmini M.   Sessa C.  

European Journal of Cancer, Vol. 39, Iss. 5, 2003-03 ,pp. : 675-683

Elsevier

Access to resources Recommend Favorite

The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-δ dependent manner

By Hampson Peter   Kavanagh Dean   Smith Emily   Wang Keqing   Lord Janet   Ed Rainger G.  

Cancer Immunology, Immunotherapy, Vol. 57, Iss. 8, 2008-08 ,pp. : 1241-1251

Springer Publishing Company

Access to resources Recommend Favorite

Cytotoxic and Antitumor Potentialities of Aporphinoid Alkaloids

By  

Current Medicinal Chemistry - Anti-Cancer Agents, Vol. 5, Iss. 2, 2005-03 ,pp. : 173-182

Bentham Science Publishers

Access to resources Recommend Favorite

Orlistat, a novel potent antitumor agent for ovarian cancer: proteomic analysis of ovarian cancer cells treated with Orlistat

By                          

International Journal of Oncology, Vol. 41, Iss. 2, 2012-01 ,pp. : 523-532

Spandidos Publications

Access to resources Recommend Favorite